Gene Therapy Alleviates Transfusion Burden in Patients With Beta-Thalassemia
Treatment with gene therapy reduced or eliminated the need for long-term red blood–cell (RBC) transfusions in some patients with severe, transfusion-dependent beta-thalassemia, according to...
Venetoclax Outperforms Standard Chemo-Immunotherapy in the Treatment of Relapsed/Refractory CLL
Treatment with the BCL2 inhibitor venetoclax and rituximab led to deeper and more durable responses than the combination of bendamustine and rituximab in patients...
Long-Term Follow-up Comparing Conditioning Regimens for Patients With AML Undergoing HCT
Nearly 10 years after allogeneic hematopoietic cell transplantation (HCT), patients with acute myeloid leukemia (AML) who received either reduced-intensity conditioning or myeloablative conditioning had...
Selinexor Plus Dexamethasone Active in Heavily Refractory Myeloma
In phase I trials, the first-in-class selective inhibitor of XPO1 selinexor (with or without low-dose dexamethasone) showed clinical activity against several types of hematologic...
Multiple Myeloma Outcomes Differ Based on Socioeconomic Factors
Despite the gains made in improving treatment for and care of patients with multiple myeloma (MM), disparities persist based on race and socioeconomic status....
Weighing the Global Cancer Burden: CONCORD-3 Finds Cancer Survival Varies by Location
Five-year cancer survival rates are increasing globally, but disparities exist between regions, according to results from the CONCORD-3 global cancer surveillance program published in...
Aspirin as Effective as Rivaroxaban for Preventing VTE After Total Hip or Knee Arthroplasty
Standard aspirin is as effective as the newer, direct oral anticoagulant (DOAC) rivaroxaban for preventing venous thromboembolism (VTE) in patients who have undergone total...
Mixed Results From SIMPLIFY-1 Complicate Myelofibrosis Treatment Decisions
The Janus kinase (JAK) inhibitor ruxolitinib is the only U.S. Food and Drug Administration–approved therapy for myelofibrosis (MF), but the resultant hematologic adverse events...
Combination Brentuximab Vedotin and Bendamustine Safe and Effective for Heavily Pretreated HL
Coupling the anti-CD30 antibody drug conjugate brentuximab vedotin with bendamustine may offer an effective salvage regimen for patients with relapsed/refractory Hodgkin lymphoma (HL), according...
Long-Term FOLL05-Up: R-CHOP Outperforms R-FM and R-CVP for Advanced-Stage Follicular Lymphoma
In 2005, the FOLL05 trial sought to determine the optimal immunochemotherapy (ICT) regimen for firstline treatment of advanced-stage follicular lymphoma (FL): R-CVP (rituximab, cyclophosphamide,...
Current Issue
May 2018, Volume 4, Issue 6
This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.
